Tenofovir is Associated With Higher Risk of Kidney Function Decline Than Entecavir in Patients With Chronic Hepatitis B.

Of the antiviral agents currently available to patients with chronic hepatitis B (CHB), entecavir (ETV) and tenofovir disoproxil fumarate (TDF) are 2 of 3 first-line agents. Given the well-known renal and bone toxicity associated with TDF, major international hepatitis B virus treatment guidelines recommend ETV over TDF in patients with predisposing factors to kidney function decline. However, as evidenced by recent studies, nephrotoxicity of antiviral agents is still an issue under debate. Therefore, we investigated the differences in the risk of kidney function decline in patients with treatment-naive CHB who were treated with ETV or TDF.